Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Transcription profiling of human blood from acute promyelocytic leukemia patients using different differentiating agents


ABSTRACT: Differentiating agents have been proposed to overcome the impaired cellular differentiation in acute myeloid leukemia (AML). However, only the combinations of all-trans retinoic acid or arsenic trioxide with chemotherapy have been successful, and only in treating acute promyelocytic leukemia (also called AML3). Here we showed that iron homeostasis is an effective target in the treatment of AML. Iron chelating therapy induces the differentiation of leukemia blasts and normal bone marrow precursors into monocytes/macrophages in a manner involving modulation of reactive oxygen species expression and the activation of mitogen-activated protein kinases (MAPK). Thirty percent of the genes most strongly induced by iron deprivation are also targeted by vitamin D3 (VD), a well-known differentiating agent. Iron chelating agents induce expression and phosphorylation of the VD receptor, and iron deprivation and VD act synergistically. VD magnifies activation of MAPK JNK and the induction of VD receptor target genes. When used to treat one AML patient refractory to chemotherapy, the combination of iron chelating agents and VD resulted in reversal of pancytopenia and blast differentiation. We propose that iron availability modulates myeloid cell commitment, and that targeting this cellular differentiation pathway together with conventional differentiating agents provides new therapeutic modalities for AML. This study presents 8 arrays 4x44K Agilent.

ORGANISM(S): Homo sapiens

SUBMITTER: Philippe DESSEN 

PROVIDER: E-TABM-925 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications


Differentiating agents have been proposed to overcome the impaired cellular differentiation in acute myeloid leukemia (AML). However, only the combinations of all-trans retinoic acid or arsenic trioxide with chemotherapy have been successful, and only in treating acute promyelocytic leukemia (also called AML3). We show that iron homeostasis is an effective target in the treatment of AML. Iron chelating therapy induces the differentiation of leukemia blasts and normal bone marrow precursors into  ...[more]

Similar Datasets

2009-03-12 | E-TABM-611 | biostudies-arrayexpress
2010-09-11 | E-TABM-792 | biostudies-arrayexpress
2010-03-18 | E-TABM-899 | biostudies-arrayexpress
2009-03-19 | E-TABM-549 | biostudies-arrayexpress
2008-12-01 | E-TABM-391 | biostudies-arrayexpress
2009-09-14 | E-TABM-640 | biostudies-arrayexpress
2011-08-04 | E-TABM-1058 | biostudies-arrayexpress
2007-12-01 | E-TABM-382 | biostudies-arrayexpress
2007-07-24 | E-TABM-239 | biostudies-arrayexpress
2008-01-26 | E-TABM-211 | biostudies-arrayexpress